A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel

A Phase I/II Double-Blind, Randomized Study of the Safety, Tolerability and Systemic Absorption of TMC120 Vaginal Microbicide Gel and Matching Placebo in Healthy HIV-Negative Women.

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00303576

Enrollment

112

Registered

2006-03-17

Start date

2005-10-31

Completion date

2006-07-31

Last updated

2006-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

HIV-1, HIV Seronegativity

Brief summary

Approximately 112 HIV-negative women, aged 18 to 50, will be enrolled in this multicenter study at four sites. Volunteers will be randomized to dapivirine (TMC120) vaginal gel or matching placebo gel. The volunteers will receive investigational product for a total of 42 days. Volunteers will be monitored on days 7, 28 and 42 for safety, tolerability and compliance.

Interventions

DRUGdapivirine (TMC120) vaginal gel

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* HIV-negative * Willing to participate and sign an informed consent * Willing to be tested for HIV, use an experimental vaginal gel, and to be randomized to a study group that includes the possibility of being assigned to a placebo group. * Willing to use two forms of contraception during the study. * Willing to undergo pelvic examinations with colposcopy and photographic documentation according to the protocol throughout the study. * Have a regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses. * Willing to abstain from using any vaginal product (other than the study product or placebo). * Willing to be sexually abstinent from randomization until completion of Day 7 evaluations.

Exclusion criteria

* Currently pregnant or breast-feeding. * Clinically detectable genital abnormality on the vulva, vaginal walls or cervix. * Laboratory confirmed gonorrhea, chlamydia, trichomonas, syphilis, or vaginal candidiasis or clinically diagnosed genital ulcer disease or active HSV-2 lesions. * Breakthrough bleeding or gynecologic surgery within 60 days prior to randomization. * Symptomatic bacterial vaginosis and unwilling to undergo treatment. * Women who require treatment for tuberculosis (TB) within 21 days prior to randomization.

Design outcomes

Primary

Measure	Time frame
Local and systemic safety and tolerability.	—

Countries

Rwanda, South Africa, Tanzania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026